MolDX: Androgen Receptor Variant (AR-V7) Protein Test Final LCD - Effective December 06, 2020

This Local Coverage Determination (LCD) has completed the Open Public Meeting and comment period and is now finalized under contractor numbers: 01112 (NCA), 01182 (SCA), 01212 (AS, GU, HI, NMI), and 01312 (NV). Responses to comments received may be found as a link at the bottom of the final LCD.

Medicare Coverage Database (MCD) Number/Contractor Determination Number: L37746
LCD Title: MolDX: Androgen Receptor Variant (AR-V7) Protein Test
FORMERLY: MolDX: Oncotype DX AR-V7 Nucleus Detect for Men with Metastatic Castrate Resistant Prostate Cancer (MCRPC)
Effective Date: December 06, 2020
Summary of LCD: Limited coverage for an Androgen Receptor splice variant 7 messenger RNA protein test (AR-V7) to help determine which patients with metastatic castrate resistant prostate cancer or other androgen receptor containing tumors may benefit from androgen receptor signaling inhibitor therapy and which may benefit from chemotherapy.

Visit the Future LCDs webpage to access this LCD.

            Last Updated Thu, 22 Oct 2020 18:01:31 +0000